Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortivus ABLTS:0H1Q 44 PB Ratio is 21.25 as of Aug. 20, 2026, which is 74% above its 10-year median of 12.18. GuruFocus rates LTS:0H1Q with a GF Score™ of 44/100 and a GF Value™ of kr6.51. The stock has 3 warning signs investors should review. Among 780 Medical Devices & Instruments companies, Ortivus AB ranks worse than 90.38% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-20), Ortivus AB's share price is kr5.10. Ortivus AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.24. Hence, Ortivus AB's PB Ratio of today is 21.25.
The historical rank and industry rank for Ortivus AB's PB Ratio or its related term are showing as below:
LTS:0H1Q'
s PB Ratio Range Over the Past 10 Years
Min: 5.18 Med: 12.18 Max: 230.17
Current: 8
During the past 13 years, Ortivus AB's highest PB Ratio was 230.17. The lowest was 5.18. And the median was 12.18.
LTS:0H1Q's PB Ratio is ranked worse than 90.38% of 780
companies
in the Medical Devices & Instruments industry
Industry Median: 2.135
vs LTS:0H1Q: 8.00
During the past 3 years, the average Book Value Per Share Growth Rate was -31.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ortivus AB was 112.80% per year. The lowest was -47.90% per year. And the median was -18.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ortivus AB PB Ratio Related Terms
Ortivus AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Ortivus AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Ortivus AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortivus AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ortivus AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ortivus AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Ortivus AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ortivus AB (LTS:0H1Q) has a PB Ratio of 21.25 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ortivus AB and its competitors. This is 74% above median its historical median of 12.18. Over the past decade, Ortivus AB's PB Ratio has ranged from 5.18 to 230.17. According to the industry distribution chart, Ortivus AB ranks #705 out of 780 companies in the Medical Devices & Instruments industry, placing it in the top 90.4%.
Is Ortivus AB's PB Ratio too high?
Ortivus AB's current PB Ratio of 21.25 is 74% above median its 10-year median of 12.18. Over the past 10 years, this metric has ranged from a low of 5.18 to a high of 230.17. The Medical Devices & Instruments industry median PB Ratio is 2.14. Ortivus AB's value of 21.25 is 895.3% above this industry median. Based on the distribution chart, Ortivus AB ranks #705 out of 780 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ortivus AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Ortivus AB's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ortivus AB ranks #705 out of 780 companies for PB Ratio. This places Ortivus AB in the lower half of its industry. The industry median PB Ratio is 2.14. Ortivus AB's value of 21.25 is 895.3% above this benchmark. Historically, Ortivus AB's own PB Ratio has ranged from 5.18 to 230.17 over the past decade. While the company's 10-year median is 12.18 vs. the industry median of 2.14, Ortivus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.14, based on 780 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ortivus AB's current PB Ratio of 21.25 is 895.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ortivus AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortivus AB's current PB Ratio is 21.25, which is 74% above median its own 10-year median of 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortivus AB stock overvalued right now?
Ortivus AB (LTS:0H1Q) has a current PB Ratio of 21.25. The stock's GF Value™ is kr6.51, compared to a current price of kr5.10 — trading 21.7% below its estimated fair value. The current PB Ratio is 21.25, which is 74% above median its 10-year median of 12.18 and 895.3% above the Medical Devices & Instruments industry median of 2.14. Ortivus AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ortivus AB (LTS:0H1Q), the current PB Ratio is 21.25 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortivus AB (LTS:0H1Q) Overvalued in 2026?
Based on GuruFocus' analysis, Ortivus AB stock appears to be undervalued.
The current stock price of kr5.10 is trading 21.7% below its estimated GF Value™ of kr6.51.
Key valuation signals for LTS:0H1Q:
PB Ratio: 21.25 (74% above median its 10-year median of 12.18)
GF Value™: kr6.51 vs. price of kr5.10 (21.7% below fair value)
Industry Position: 895.3% above the Medical Devices & Instruments median (#705 of 780)
No single metric tells the full story. See the LTS:0H1Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. The company has developed an user-friendly solutions that supports diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating its solutions with electronic health records, dispatch systems, and national registries, the company ensures fast and secure information management and more integrated care process. Its product portfolio includes MobiMed ePR, MobiMed Monitor, MobiMed FleetCtrl, MobiMed Life, and others.
44GF Score
Get the complete analysis for LTS:0H1Q
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H1Q has been successfully added to your 
